Literature DB >> 12842042

The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding.

Jordan H Chill1, Sabine R Quadt, Rina Levy, Gideon Schreiber, Jacob Anglister.   

Abstract

The potent antiviral and antiproliferative activities of human type I interferons (IFNs) are mediated by a single receptor comprising two subunits, IFNAR1 and IFNAR2. The structure of the IFNAR2 IFN binding ectodomain (IFNAR2-EC), the first helical cytokine receptor structure determined in solution, reveals the molecular basis for IFN binding. The atypical perpendicular orientation of its two fibronectin domains explains the lack of C domain involvement in ligand binding. A model of the IFNAR2-EC/IFNalpha2 complex based on double mutant cycle-derived constraints uncovers an extensive and predominantly aliphatic hydrophobic patch on the receptor that interacts with a matching hydrophobic surface of IFNalpha2. An adjacent motif of alternating charged side chains guides the two proteins into a tight complex. The binding interface may account for crossreactivity and ligand specificity of the receptor. This molecular description of IFN binding should be invaluable for study and design of IFN-based biomedical agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842042     DOI: 10.1016/s0969-2126(03)00120-5

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  27 in total

1.  Protein structure prediction using sparse dipolar coupling data.

Authors:  Youxing Qu; Jun-tao Guo; Victor Olman; Ying Xu
Journal:  Nucleic Acids Res       Date:  2004-01-26       Impact factor: 16.971

2.  Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection.

Authors:  Martynas Gavutis; Suman Lata; Peter Lamken; Pia Müller; Jacob Piehler
Journal:  Biophys J       Date:  2005-03-18       Impact factor: 4.033

3.  The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.

Authors:  Zongli Li; Jennifer Julia Strunk; Peter Lamken; Jacob Piehler; Thomas Walz
Journal:  J Mol Biol       Date:  2007-12-08       Impact factor: 5.469

4.  Observation of intermolecular interactions in large protein complexes by 2D-double difference nuclear Overhauser enhancement spectroscopy: application to the 44 kDa interferon-receptor complex.

Authors:  Ilona Nudelman; Sabine R Akabayov; Tali Scherf; Jacob Anglister
Journal:  J Am Chem Soc       Date:  2011-08-23       Impact factor: 15.419

5.  Functional characterization of canine interferon-lambda.

Authors:  Wenhui Fan; Lei Xu; Liqian Ren; Hongren Qu; Jing Li; Jingjing Liang; Wenjun Liu; Limin Yang; Tingrong Luo
Journal:  J Interferon Cytokine Res       Date:  2014-06-20       Impact factor: 2.607

Review 6.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

7.  IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques.

Authors:  Matthew P Morrow; Jian Yan; Panyupa Pankhong; Devon J Shedlock; Mark G Lewis; Kendra Talbott; Roberta Toporovski; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

8.  Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Steven A Berkowitz; Damian Houde
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-29       Impact factor: 3.109

9.  Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family.

Authors:  Dorothee Preimel; Heinrich Sticht
Journal:  J Mol Model       Date:  2004-07-09       Impact factor: 1.810

Review 10.  Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.

Authors:  Jacob Piehler; Christoph Thomas; K Christopher Garcia; Gideon Schreiber
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.